Literature DB >> 18217702

Large neutral amino acid transporter enables brain drug delivery via prodrugs.

Mikko Gynther1, Krista Laine, Jarmo Ropponen, Jukka Leppänen, Anne Mannila, Tapio Nevalainen, Jouko Savolainen, Tomi Järvinen, Jarkko Rautio.   

Abstract

The blood-brain barrier efficiently controls the entry of drug molecules into the brain. We describe a feasible means to achieve carrier-mediated drug transport into the rat brain via the specific, large neutral amino acid transporter (LAT1) by conjugating a model compound to L-tyrosine. A hydrophilic drug, ketoprofen, that is not a substrate for LAT1 was chosen as a model compound. The mechanism and the kinetics of the brain uptake of the prodrug were determined with an in situ rat brain perfusion technique. The brain uptake of the prodrug was found to be concentration-dependent. In addition, a specific LAT1 inhibitor significantly decreased the brain uptake of the prodrug. Therefore, our results reveal for the first time that a drug-substrate conjugate is able to transport drugs into the brain via LAT1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18217702     DOI: 10.1021/jm701175d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  44 in total

1.  Molecular and functional characterization of riboflavin specific transport system in rat brain capillary endothelial cells.

Authors:  Mitesh Patel; Ramya Krishna Vadlapatla; Dhananjay Pal; Ashim K Mitra
Journal:  Brain Res       Date:  2012-06-07       Impact factor: 3.252

Review 2.  Targeting the neurovascular unit for treatment of neurological disorders.

Authors:  Reyna L Vangilder; Charles L Rosen; Taura L Barr; Jason D Huber
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

3.  Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.

Authors:  Lauri Peura; Kalle Malmioja; Kristiina Huttunen; Jukka Leppänen; Miia Hämäläinen; Markus M Forsberg; Mikko Gynther; Jarkko Rautio; Krista Laine
Journal:  Pharm Res       Date:  2013-10       Impact factor: 4.200

4.  Mechanism of brain targeting by dexibuprofen prodrugs modified with ethanolamine-related structures.

Authors:  Yanping Li; Yangyang Zhou; Jiayu Jiang; Xinyi Wang; Yao Fu; Tao Gong; Xun Sun; Zhirong Zhang
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-08       Impact factor: 6.200

Review 5.  Prodrug approaches for CNS delivery.

Authors:  Jarkko Rautio; Krista Laine; Mikko Gynther; Jouko Savolainen
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

6.  Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy.

Authors:  Santimukul Santra; Charalambos Kaittanis; Oscar J Santiesteban; J Manuel Perez
Journal:  J Am Chem Soc       Date:  2011-09-27       Impact factor: 15.419

7.  LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs.

Authors:  Evan Augustyn; Karissa Finke; Arik A Zur; Logan Hansen; Nathan Heeren; Huan-Chieh Chien; Lawrence Lin; Kathleen M Giacomini; Claire Colas; Avner Schlessinger; Allen A Thomas
Journal:  Bioorg Med Chem Lett       Date:  2016-04-11       Impact factor: 2.823

Review 8.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

9.  Blood-brain barrier permeability and brain uptake mechanism of kainic acid and dihydrokainic acid.

Authors:  Mikko Gynther; Aleksanteri Petsalo; Steen H Hansen; Lennart Bunch; Darryl S Pickering
Journal:  Neurochem Res       Date:  2014-12-09       Impact factor: 3.996

10.  LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates.

Authors:  Arik A Zur; Huan-Chieh Chien; Evan Augustyn; Andrew Flint; Nathan Heeren; Karissa Finke; Christopher Hernandez; Logan Hansen; Sydney Miller; Lawrence Lin; Kathleen M Giacomini; Claire Colas; Avner Schlessinger; Allen A Thomas
Journal:  Bioorg Med Chem Lett       Date:  2016-09-03       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.